These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1753253)

  • 1. Galanthamine treatment in Alzheimer's disease.
    Dal-Bianco P; Maly J; Wôber C; Lind C; Koch G; Hufgard J; Marschall I; Mraz M; Deecke L
    J Neural Transm Suppl; 1991; 33():59-63. PubMed ID: 1753253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study.
    Babić T; Mahović Lakusić D; Sertić J; Petrovecki M; Stavljenić-Rukavina A
    Coll Antropol; 2004 Jun; 28(1):199-204. PubMed ID: 15636076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
    Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
    Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
    Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
    Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
    Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Galanthamine versus donepezil in the treatment of Alzheimer's disease].
    López-Pousa S; Garre-Olmo J; Vilalta-Franch J
    Rev Neurol; 2007 Jun 1-15; 44(11):677-84. PubMed ID: 17557224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
    Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
    Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the acetylcholinesterase inhibitor galanthamine.
    Sramek JJ; Frackiewicz EJ; Cutler NR
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2393-402. PubMed ID: 11060814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A naturalistic study of galantamine for Alzheimer's disease.
    Brodaty H; Woodward M; Boundy K; Barnes N; Allen G;
    CNS Drugs; 2006; 20(11):935-43. PubMed ID: 17044730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
    Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01).
    Caramelli P; Chaves ML; Engelhardt E; Machado JC; Schultz RR; Vale FA; Charchat-Fichman H;
    Arq Neuropsiquiatr; 2004 Jun; 62(2B):379-84. PubMed ID: 15273830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
    Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
    J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine improves gait performance in patients with Alzheimer's disease.
    Assal F; Allali G; Kressig RW; Herrmann FR; Beauchet O
    J Am Geriatr Soc; 2008 May; 56(5):946-7. PubMed ID: 18454755
    [No Abstract]   [Full Text] [Related]  

  • 19. Galantamine treatment in outpatients with mild Alzheimer's disease.
    Richarz U; Gaudig M; Rettig K; Schauble B
    Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
    Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
    CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.